Hemofiltration is a key tool in the treatment of patients with Acute Renal Failure (ARF). In July 2006, Normocarb HF received FDA approval as the first and only lactate- and dextrose-free hemofiltration solution (infusate) for use in a CRRT circuit. No matter what your role is in the treatment of these complex patients, Normocarb HF should be your first choice of solution.
Normocarb HF Approved by FDA
On July 26th, 2006 Dialysis Solutions Inc. received an NDA approval from the FDA for their new product Normocarb HF. Normocarb HF is a hemofiltration or replacement solution approved for direct infusion into a CRRT circuit in the treatment of acute renal failure. Normocarb HF will be available with bicarbonate concentrations of 25mmol/L and 35mmol/L.
Normocarb HF will be launched in the US market in October of 2006.
Dialysis Solutions Inc. has been manufacturing specialty bicarbonate based solutions for the CRRT market in North America since 2002. Normocarb was the first bicarbonate based dialysate solution to be commercialized.